精准基因组检测市场 - 全球产业规模、份额、趋势、机会和预测，按技术、按产品和服务（消耗品、设备、服务）、按应用、按最终用途、按地区和竞争进行细分，2020 年至 2030 年

2024 年全球精准基因组检测市值为 155.1 亿美元，预计到 2030 年将达到 209.8 亿美元，预测期内的年复合成长率(CAGR) 为 5.12%。由于基因组定序技术的进步、个人化医疗的日益普及以及遗传疾病和癌症发病率的上升，市场正在迅速扩大。精准基因组检测包括分析个人的 DNA，以评估疾病易感性、提供治疗决策依据以及根据基因图谱定制医疗干预措施。随着全球医疗保健系统向精准医疗转变，基因组检测正在成为现代诊断和治疗的基本组成部分。

次世代定序（NGS）在降低基因组检测成本和提高效率方面发挥了关键作用，能够快速定序整个基因组、外显子组或目标基因组以进行全面的基因分析。这使得基因组检测更容易用于临床应用，例如癌症诊断、遗传疾病筛检和药物基因组学。此外，Oxford Nanopore 和 PacBio 的 SMRT 定序等第三代定序 (TGS) 技术的发展进一步提高了 DNA 分析的准确性和效率。

主要市场驱动因素

遗传疾病和癌症发生率不断上升

主要市场挑战

成本高且可近性有限

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第四章：COVID-19 对全球精准基因组检测市场的影响

第五章：全球精准基因组检测市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依技术分类（次世代定序、聚合酶炼式反应、微阵列技术、桑格定序、CRISPR/Cas 系统、其他）
  • 依产品及服务（耗材（试剂盒及试剂）、设备、服务）
  • 依应用分类（肿瘤学、心血管疾病、神经系统疾病、生殖健康、罕见疾病、其他）
  • 按最终用途医院和诊所、诊断实验室、研究和学术机构、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美精准基因组检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第七章：欧洲精准基因组检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太精准基因组检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲精准基因组检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲精准基因组检测市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：全球精准基因组检测市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences Holdings Inc.
• GenScript Biotech
• QIAGEN NV
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

第 16 章：策略建议

第17章 调査会社について・免责事项

The Global Precision Genomic Testing Market was valued at USD 15.51 billion in 2024 and is projected to reach USD 20.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.12% during the forecast period. The market is expanding rapidly due to advancements in genomic sequencing technologies, the increasing adoption of personalized medicine, and the rising prevalence of genetic disorders and cancers. Precision genomic testing involves analyzing an individual's DNA to assess disease predisposition, inform treatment decisions, and customize medical interventions based on genetic profiles. As healthcare systems globally shift toward precision medicine, genomic testing is becoming a fundamental component of modern diagnostics and therapeutics.

Next-generation sequencing (NGS) has played a key role in reducing the costs and enhancing the efficiency of genomic testing, enabling the rapid sequencing of entire genomes, exomes, or targeted gene panels for comprehensive genetic analysis. This has made genomic testing more accessible for clinical applications, such as cancer diagnostics, hereditary disease screening, and pharmacogenomics. Additionally, the development of third-generation sequencing (TGS) technologies, like Oxford Nanopore and PacBio's SMRT sequencing, has further improved the accuracy and efficiency of DNA analysis.

Key Market Drivers

Increasing Prevalence of Genetic Disorders and Cancer

The global precision genomic testing market is experiencing significant growth, driven by the increasing prevalence of genetic disorders and cancer worldwide. Precision genomic testing supports early detection, accurate diagnosis, and personalized treatment by analyzing an individual's genetic makeup. As demand for targeted therapies and precision medicine rises, the genomic testing market continues to expand, offering promising advancements in healthcare.

According to the CDC, when one parent carries an autosomal dominant disease, each child has a 50% chance of inheriting the associated genetic mutation. The rising prevalence of genetic disorders such as cystic fibrosis, sickle cell anemia, and Huntington's disease, largely due to greater awareness and improved diagnostic capabilities, is further driving market demand. Many inherited diseases require precise genetic analysis for proper diagnosis and management, making genomic testing a critical tool in modern medicine. Moreover, the growing use of whole genome sequencing and NGS technologies has enhanced the ability to identify genetic mutations linked to various hereditary conditions.

With approximately 10,000 distinct types of monogenic diseases-resulting from mutations in a single gene-that affect about 10 in every 1,000 people, the global prevalence of these diseases is estimated at 70 to 80 million individuals. Furthermore, cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed annually. Precision genomic testing plays a vital role in oncology by identifying genetic mutations that contribute to tumor formation.

Key Market Challenges

High Costs and Limited Accessibility

One of the primary challenges in the precision genomic testing market is the high cost associated with genomic sequencing and analysis. Advanced tests such as whole genome sequencing require sophisticated technologies, specialized expertise, and robust bioinformatics infrastructure, contributing to their high cost. Many healthcare systems, particularly in developing regions, face difficulties in integrating these services due to limited funding and the absence of reimbursement policies. Consequently, access to precision genomic testing remains restricted, limiting its broader adoption among patients who could benefit from early diagnosis and personalized treatment.

Key Market Players

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences
• GenScript Biotech
• QIAGEN N.V.
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

Report Scope

This report segments the Global Precision Genomic Testing Market as follows, detailing the industry trends:

Market by Technology:

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Microarray Technology
• Sanger Sequencing
• CRISPR/Cas Systems
• Others

Market by Product & Service:

• Consumables
• Equipment
• Services

Market by Application:

• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Reproductive Health
• Rare Diseases
• Others

Market by End Use:

• Hospitals and Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others

Market by Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

Company Profiles: A detailed analysis of the major players in the Global Precision Genomic Testing Market.

Available Customizations:

TechSci Research offers customization options for the Global Precision Genomic Testing Market report, tailored to meet a company's specific needs.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Precision Genomic Testing Market

5. Global Precision Genomic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others)
  • 5.2.2. By Product & Services (Consumables (Kits & Reagents), Equipment, Services)
  • 5.2.3. By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others)
  • 5.2.4. By End-Use Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Precision Genomic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product & Services
  • 6.2.3. By Application
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Genomic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product & Services
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Mexico Precision Genomic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product & Services
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Canada Precision Genomic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product & Services
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Precision Genomic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product & Services
  • 7.2.3. By Application
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Precision Genomic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product & Services
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. Germany Precision Genomic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product & Services
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Precision Genomic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product & Services
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Precision Genomic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product & Services
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Precision Genomic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product & Services
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia Pacific Precision Genomic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product & Services
  • 8.2.3. By Application
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Genomic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product & Services
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Precision Genomic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product & Services
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. South Korea Precision Genomic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product & Services
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. Japan Precision Genomic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product & Services
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Precision Genomic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product & Services
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. South America Precision Genomic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product & Services
  • 9.2.3. By Application
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Precision Genomic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product & Services
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Precision Genomic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product & Services
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Precision Genomic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product & Services
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Precision Genomic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product & Services
  • 10.2.3. By Application
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Precision Genomic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product & Services
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Precision Genomic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product & Services
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Precision Genomic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product & Services
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Genomic Testing Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Revvity, Inc.
• 15.4. Maravai LifeSciences Holdings Inc.
• 15.5. GenScript Biotech
• 15.6. QIAGEN N.V.
• 15.7. PacBio Biosciences Inc.
• 15.8. Oxford Nanopore Technologies plc.
• 15.9. Illumina, Inc.
• 15.10. 10x Genomics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer